Results 161 to 170 of about 32,216 (248)

Menopausal status at the age of 46: Its association with depressive and anxiety symptoms and morbidity in women—A northern Finland birth cohort 1966 study

Acta Obstetricia et Gynecologica Scandinavica, EarlyView.
Women who are perimenopausal or menopausal at age 46 have a higher risk of anxiety and depressive symptoms than premenopausal women. Early‐onset menopause highlights the need for mental health support during and after the menopausal transition. Abstract Introduction The incidence of several morbidities increases during the menopausal transition ...
Tiia Saarinen, Susanna M. Savukoski, Paula Pesonen, Jouko Miettunen, Maarit Niinimäki   +4 more
wiley   +1 more source

Vitrification alters growth differentiation factor 9 and follicle-stimulating hormone receptor expression in human cumulus-mural granulosa cells. [PDF]

Clin Exp Reprod Med
Sirait B, Wiweko B, Handayani N, Sundari AM, Muharam R, Jusuf AA, Suryandari DA, Rachman IA, Widyahening IS, Boediono A.   +9 more
europepmc   +1 more source

Gold‐standard evidence and best practice guidance for menstrual cycle‐informed clinical care: An overview for clinicians

British Journal of Clinical Psychology, EarlyView.
Abstract Objectives To synthesize current evidence and provide clinically actionable recommendations for integrating menstrual cycle‐related processes—particularly hormone sensitivity, Premenstrual Dysphoric Disorder (PMDD) and Premenstrual Exacerbation (PME)—into psychological assessment, formulation and treatment.
Ellen R. Lambert, Louise N. Nolan, Katja M. Schmalenberger   +2 more
wiley   +1 more source

Pharmacological rescue of follicle-stimulating hormone receptor mutants. In vitro and in silico studies.

Endocrinology
Zariñán T, Jardón-Valadez E, Gutiérrez-Sagal R, Ulloa-Pérez E, Nataraja S, Yu HN, Ulloa-Aguirre A.   +6 more
europepmc   +1 more source

Current Approaches to Support Patients to Withdraw From Image and Performance Enhancing Drugs

Clinical Endocrinology, EarlyView.
ABSTRACT Image and performance‐enhancing drugs (IPEDs) include agents such as androgens, growth hormone, and erythropoietin, which are used to enhance appearance and physical performance. Androgens, also known as anabolic‐androgenic steroids (AAS), are the most used IPEDs worldwide.
Elizabeth Hyams, Bonnie Grant, Richard Quinton, Channa N. Jayasena   +3 more
wiley   +1 more source

A follicle-stimulating hormone receptor-targeted near-infrared fluorescent probe for tumor-selective imaging and photothermal therapy. [PDF]

Mater Today Bio
Liu Q, Pu T, Zhou X, Sun J, Yuan W, Zhang S, Zhang M, Zhang M, Peng J, Li F, Zhang X, Xu C.   +11 more
europepmc   +1 more source

International consensus recommendations for identifying malnutrition in children with neurological impairment

Developmental Medicine &Child Neurology, EarlyView.
Abstract Children with neurological impairment (CNI) are at increased risk of malnutrition because of functional, medical, and socioeconomic challenges. However, difficulties in obtaining reliable anthropometric measurements and differences in body composition limit the usefulness of conventional nutritional indicators.
Sarah Vermilyea, Jodi Wolff, Gina Rempel, Jessie M. Hulst, Koen Huysentruyt, Mandy Neudecker, Denise Kennedy, Valérie Marchand, Erika Ochoa‐Ortiz, Richard D. Stevenson, Promoting International Collaboration for Nutrition in Neurological Impairment in Children (PICNNIC) Working Group, Lucinda Lourens, Mark Conaway, Tejas S. Desai, Mercedes Ruiz Brunner, Nathalia Sanchez Vargas, Valeria Martinez Tenorio, Kristie L. Bell, Claudio Romano, Richard Grossberg   +19 more
wiley   +1 more source

Synergistic Effects of Chemotherapy and Phototherapy on Ovarian Cancer Using Follicle-Stimulating Hormone Receptor-Mediated Liposomes Co-Loaded with SN38 and IR820. [PDF]

Pharmaceutics
Pian L, Zeng B, Wang N, Wang S, Wu H, Wan H, Chen L, Huang W, Gao Z, Jin D, Jin M.   +10 more
europepmc   +1 more source

Follicle-stimulating hormone receptor autoantibody associated primary ovarian insufficiency successfully treated with corticosteroids: a case report. [PDF]

F S Rep, 2020
Riestenberg C, Ahern S, Shamonki M.
europepmc   +1 more source

Weight Regain After Incretin Treatment: The Lean Mass Deficit Hypothesis and a Role for Testosterone Combination Therapy in Men

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), dual glucose‐dependent insulinotropic polypeptide (GIP)/GLP‐1RA and triple (GIP)/GLP‐1RA/glucagon agonists achieve placebo‐subtracted weight loss of 15% to 22%. Their long‐term value depends on how well the weight loss is maintained and on the composition of weight loss, not only
Michael Zitzmann, Zsolt Bosnyak, Richard Jones, Monica Caliber   +3 more
wiley   +1 more source